Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A highly potent antibody effective against SARS-CoV-2 variants of concern
Craig Fenwick, Priscilla Turelli, Laurent Perez, et al.
Cell Reports (2021) Vol. 37, Iss. 2, pp. 109814-109814
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 196
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 138
De novo design of protein interactions with learned surface fingerprints
Pablo Gaínza, Sarah Wehrle, Alexandra Van Hall‐Beauvais, et al.
Nature (2023) Vol. 617, Iss. 7959, pp. 176-184
Open Access | Times Cited: 114
Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes
Juan Rodriguez-Rivas, Giancarlo Croce, Maureen Muscat, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 4
Open Access | Times Cited: 80
Advances and gaps in SARS-CoV-2 infection models
César Muñoz‐Fontela, Lina Widerspick, Randy A. Albrecht, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 1, pp. e1010161-e1010161
Open Access | Times Cited: 77
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
Craig Fenwick, Priscilla Turelli, Céline Pellaton, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 605
Open Access | Times Cited: 85
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 51
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Craig Fenwick, Priscilla Turelli, Dongchun Ni, et al.
Nature Microbiology (2022) Vol. 7, Iss. 9, pp. 1376-1389
Open Access | Times Cited: 39
Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range
Dongchun Ni, Priscilla Turelli, Bertrand Beckert, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1011206-e1011206
Open Access | Times Cited: 21
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort
Dominik Menges, Kyra D. Zens, Tala Ballouz, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Rational Development of Hypervalent Glycan Shield‐Binding Nanoparticles with Broad‐Spectrum Inhibition against Fatal Viruses Including SARS‐CoV‐2 Variants
Ying Li, Shuxin Xu, Qing Ye, et al.
Advanced Science (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 22
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies
Norman Moullan, Josephat Asiago, Kathryn Stecco, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 1, pp. 173-187
Open Access | Times Cited: 4
Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces
Joseph H. Lubin, Christopher Markosian, D. Balamurugan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 22
Glyco engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues
Somanath Kallolimath, Roman Palt, Esther Föderl-Höbenreich, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Unravelling Insights into the Evolution and Management of SARS-CoV-2
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
BioMedInformatics (2024) Vol. 4, Iss. 1, pp. 385-409
Open Access | Times Cited: 2
Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein
Yu‐Lei Chen, Jin-Jin Lin, Huan Ma, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10904-10904
Open Access | Times Cited: 12
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
Delphine D. Acar, Wojciech Witkowski, Magdalena Wejda, et al.
EBioMedicine (2024) Vol. 100, pp. 104960-104960
Open Access | Times Cited: 2
Therapeutic antibodies and alternative formats against SARS-CoV-2
Rahel R. Winiger, Laurent Perez
Antiviral Research (2024) Vol. 223, pp. 105820-105820
Open Access | Times Cited: 2
Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range
Dongchun Ni, Priscilla Turelli, Bertrand Beckert, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
P2G3 human monoclonal antibody neutralizes SARS-CoV-2 Omicron subvariants including BA.4 and BA.5 and Bebtelovimab escape mutants
Priscilla Turelli, Craig Fenwick, Charlène Raclot, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
Masaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, et al.
iScience (2022) Vol. 25, Iss. 12, pp. 105596-105596
Open Access | Times Cited: 11
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19
Hakim Hocini, Aurélie Wiedemann, Fabiola Blengio, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 5, pp. 882-893
Open Access | Times Cited: 6
Outpatient treatment options to address the SARS-CoV-2 variant Omicron
Matthew W. McCarthy
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 8, pp. 1129-1133
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top